Tag - CGEN

Markets

SVB Leerink starts Compugen at OP; PT $15

SVB Leerink launched coverage of Compugen (NASDAQ:CGEN) with an “outperform” rating and $15 price target. The stock closed at $13.22 on May 6. “TIGIT / PVRIG could be the next evolution in immune checkpoint blockade...

May 7, 2020

Developments

Compugen doses first patient in advanced solid tumor trial

Compugen (NASDAQ:CGEN) dosed the first patient in its Phase 1 trial of COM701, in combination with Opdivo, in patients with advanced solid tumors. The Phase 1 study will assess the safety and tolerability of COM701, a...

May 21, 2019

Tag - CGEN

SVB Leerink starts Compugen at OP; PT $15

Compugen doses first patient in advanced solid tumor trial

General

More